'Attempt at Coercion'? Federal Reserve Chair Jerome Powell Faces Criminal Probe
"The threat of criminal charges is a consequence of the Federal Reserve setting interest rates based on our best assessment of what will serve the public, rather than following the preferences of the President," Federal Reserve Chair Jerome Powell said in response to a U.S. Department of Justice criminal investigation targeting Powell over testimony he previously delivered to Congress.
Disney-OpenAI's Sora Deal: What it Signals for Licensing and Responsible AI
The Walt Disney Co.'s newly announced licensing agreement with OpenAI marks a pivotal moment at the intersection of intellectual property and generative AI. For rights holders, platforms and brands, the deal illustrates an emerging blueprint for commercializing iconic IP in AI-native formats while attempting to manage legal, regulatory, and reputational risk.
How I Made Partner: 'Don't Be Afraid to Evolve Your Practice,' Says Arianna Evers of WilmerHale
"Don't be afraid to evolve your practice. If you discover you have a passion for an area that's different from what you started in, it's okay to pivot. Shifts can feel risky, but if your curiosity is pulling you in that direction and you see opportunity, embrace it. Developing expertise in an area you're truly excited about will make you more motivated and valuable."
NLRB Facing Political, Structural Challenges 91 Years After Founding
The National Labor Relations Board has mostly succeeded as a neutral arbiter in disputes, labor law experts say. But the NLRB is hamstrung by inherent weaknesses in the board's structure and its governing statute—the National Labor Relations Act— that limit the growth of the labor movement and union participation.
$47B in Revenue: Moderna Accused of Infringing on Technology to Develop COVID-19 Vaccine, Lawsuit Says
The complaint alleges that Moderna used the patented fluorescent protein technology without permission during preclinical through phase III trials and for marketing purposes, claiming the technology was critical for Moderna's vaccine development success, which has generated over $47 billion in revenues.

